Form 4: Nuvation Bio Inc. Executive Kerry Wentworth Acquires 500,000 Stock Options
SEC Form 4 Filing
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., reports the acquisition of 500,000 stock options.
Summary
- Kerry Wentworth, the Chief Regulatory Officer of Nuvation Bio Inc., filed a Form 4 to report changes in beneficial ownership.
- The reported transaction involves the acquisition of 500,000 stock options with an exercise price of $1.87.
- These options were granted on February 29, 2024, and expire on February 27, 2034.
- The options vest as to 25% on the one-year anniversary of the grant date, and then monthly over the following 36 months, contingent upon continuous service.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a standard regulatory filing related to executive compensation. The acquisition of stock options can be seen as a slightly positive indicator of the executive's confidence in the company, but it's not a major event.
Positives
- The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects. Option grants are a common form of executive compensation in the biotech industry.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech industry.
- The vesting schedule of 25% after one year followed by monthly vesting over three years is a common structure.
- Comparing the size of the grant to similar companies and executive roles would provide further context on the significance of this grant.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of earliest transaction (grant date of stock options) |
| 02/29/2024 | Option vests as to 25% on the one year anniversary of this date. |
| 02/27/2034 | Expiration date of the stock options |
| 03/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.